Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Study of Epacadostat, Pembrolizumab, and CRS-207, With or Without Cyclophosphamide and GVAX Pancreas Vaccine in Patients With Metastatic Pancreas Cancer

Summary

8/5/2019 NOTE: There is currently 1 possible slot available. The purpose of this phase II study is to determine the recommended dose of epacadostat in different combinations, as well as assess the survival of patients in both treatment groups.

General Information

NCT#: NCT03006302
Study ID: J16173
Trial Phase: Phase II

Trial Sponsor: Johns Hopkins University
Therapies Used in This Trial: GVAX, Cyclophosphamide, CRS-207, Pembrolizumab, Epacadostat

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search